AP NEWS

Fulcrum Therapeutics to Present at Biotech Showcase 2019

January 4, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 4, 2019--Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, will present at next week’s Biotech Showcase in San Francisco.

Robert J. Gould, Ph.D., Fulcrum’s president and chief executive officer, will discuss Fulcrum’s approach to developing novel therapies for rare genetic diseases. By harnessing the breakthrough biology of gene regulation, Fulcrum aims to modulate the expression of genes known to drive disease and develop highly personalized medicines that will make a significant difference for patients who are currently without treatments.

Fulcrum’s lead program targets facioscapulohumeral muscular dystrophy (FSHD), a rare neuromuscular disorder. Fulcrum has initiated clinical trial readiness studies in FSHD in partnership with the FSHD Clinical Trial Readiness Network. In addition to muscle disorders, Fulcrum is also advancing treatments for disorders of the central nervous system and blood.

Presentation details:

Date: Tuesday, January 8, 2019 Time: 10:15 – 10:30 a.m. PST Location: Hilton San Francisco Union Square Hotel Room: Franciscan D (Ballroom Level)

About Fulcrum Therapeutics

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., has raised $135 million from two rounds of funding. Investors include Foresite Capital, Fidelity Management and Research Company, 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section 32, NS Investments, entities affiliated with Leerink Partners and undisclosed institutional investors, as well as founding investor Third Rock Ventures. Fulcrum was launched in 2016 and named a “Fierce 15” company later that year. For more information, please visit www.fulcrumtx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190104005023/en/

CONTACT: Media:

Stephanie Simon

Ten Bridge Communications

stephanie@tenbridgecommunications.com

617-581-9333

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL

SOURCE: Fulcrum Therapeutics

Copyright Business Wire 2019.

PUB: 01/04/2019 07:00 AM/DISC: 01/04/2019 07:00 AM

http://www.businesswire.com/news/home/20190104005023/en

AP RADIO
Update hourly